transform take time neutral
maintain neutral rate follow result came
slightli street top bottom line expect
head quarter low surpris see
posit reaction come in-lin quarter revenu split
btig/consensu estim organ growth adj ep number
slightli ahead estim enough move share higher
initi revenu guidanc flat revenu growth y/i
y/i report xfx stabl margin anoth year
turnaround maintain strong profit compani
improv ampl fuel growth upward inflect
share said believ easier go lose
market share subsequ grow in-lin end market
move share taker maintain neutral rate
transit believ friday print posit step forward
rosa launch import determin recon market share
receiv approv rosa knee applic januari management
feel success roll-out aid regain share knee market
detail launch messag featur sale forc
limit competit purpos management acknowledg
limit commerci roll underway continu
broad debut aao follow full roll-out
approv rosa spine applic still await fda approv
expect later
suppli issu abat npi becom focu management note
suppli stock progress made safeti stock
return end intend launch multipl product
year allow rep becom offens
suppli isnt barrier believ resolv suppli check box
investor regulatori hurdl still need clear
valuat zimmer biomet rate neutral btig
publish price target neutral rate stock
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
zimmer biomet report result overal revenu came
miss btig expect call beat
consensu expect call segment report
revenu knee hip
dental spine cmf compar
btig/consensu estim
organ revenu growth btig expect
sequenti last quarter gross margin
adjust bp btig estim cost associ inventori
initi began fade sg percentag revenu came
versu btig estim call revenu in-
line btig expect told adjust ep quarter
beat btig consensu estim call
made follow chang model
actualsbtig estimate variancetot net bpssg spend bpsr spend bpsadj ebit bpsadj ebitda bpstax bpssourc btig research estim compani filingsvari
within zbh revenu mix adjust pace sale improv linearli
year even midst zbh histor season growth
percentag lower estim overal account product
cadenc increas fx headwind
 remain consist per management commentari
brought sg account higher spend
beyond excess sg off-set lower interest payment
improv tax rate net effect adj ep previou
estim in-lin management guidanc also introduc
estim
zimmer biomet rate neutral zimmer biomet trade
estim next twelv month ep project versu comp
group forecast revenu compound-annual-growth-rate
comp group forecast ep compound-annual-growth-rate
also comp group feel discount
overal comp group warrant given zimmer biomet current top-lin
growth expect near-term challeng associ product
qualiti remedi persist margin pressur btig
publish price target neutral rate stock risk rate includ
follow upsid perspect shorter organiz turnaround
assum less regulatori challeng assum faster resolut
on-go qualiti remedi lack gm pressur strong uptak robot
better expect employe moral stronger expect price
pressur downsid perspect loss market share
addit regulatori requir cost limit robot adopt
longer expect improv compani cultur
btig research estim compani filingsnewold chang
incom etot y/i sale special oper incom incom tax expens net share net incom share gross net net oper tax expens btig research estim compani report
revenu y/i btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
